drugset
drugset / Trial / NCT04417530

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

NCT04417530 ↗

Phase 2 Completed 22 enrolled Aura Biosciences
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).

Timeline

Start
2020-08-05
Primary completion
2024-04-22
Completion
2024-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Belzupacap Sarotalocan Protein / enzyme biologic — Other

Indications

malignant choroid melanoma